British drugmaker GSK is walking away from camlipixant, an experimental chronic cough treatment it acquired in a deal worth $2 billion.
According to BioPharma Dive, GSK decided to cease development of the drug after it produced mixed results in Phase 3 testing — the final and most expensive stage of clinical trials before a medicine can seek regulatory approval. Shelving the program means the company is writing off a major bet.
Camlipixant was aimed at chronic cough, a persistent condition that has proven stubbornly hard to treat. BioPharma Dive reports that its failure makes it the third drug from its class to fall short, pointing to a broader pattern of setbacks for this particular scientific approach.
For GSK, the decision underscores the steep risks of drug development, where even treatments backed by billion-dollar acquisitions can collapse in late-stage trials after years of investment. The repeated failures across the same class of drugs also suggest the underlying strategy for tackling chronic cough may face deeper scientific hurdles than the industry hoped.
Why it matters: When a company as large as GSK abandons a $2 billion drug, it is a reminder that pharmaceutical breakthroughs are far from guaranteed — and that patients waiting on new options for hard-to-treat conditions like chronic cough may have to keep waiting.